Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grey Wolf HealthTSXV:WOLF -3.03%54 Debt-to-Equity is 0.81 as of Mar. 2026, which is 76% above its 10-year median of 0.46. GuruFocus rates TSXV:WOLF with a GF Score™ of 54/100 and a GF Value™ of C$1.09 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 562 Healthcare Providers & Services companies, Grey Wolf Health ranks worse than 68.68% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Grey Wolf Health's Debt-to-Equity or its related term are showing as below:
TSXV:WOLF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.35 Med: 0.46 Max: 5.9
Current: 0.81
During the past 5 years, the highest Debt-to-Equity Ratio of Grey Wolf Health was 5.90. The lowest was 0.35. And the median was 0.46.
TSXV:WOLF's Debt-to-Equity is ranked worse than 68.68% of 562
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs TSXV:WOLF: 0.81
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Grey Wolf Health Debt-to-Equity Related Terms
Grey Wolf Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Grey Wolf Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Grey Wolf Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grey Wolf Health Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Grey Wolf Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Grey Wolf Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grey Wolf Health (TSXV:WOLF) has a Debt-to-Equity of 0.81 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Grey Wolf Health and its competitors. This is 76% above median its historical median of 0.46. Over the past decade, Grey Wolf Health's Debt-to-Equity has ranged from 0.35 to 5.90. According to the industry distribution chart, Grey Wolf Health ranks #386 out of 562 companies in the Healthcare Providers & Services industry, placing it in the top 68.7%.
Is Grey Wolf Health's Debt-to-Equity too high?
Grey Wolf Health's current Debt-to-Equity of 0.81 is 76% above median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 5.90. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. Grey Wolf Health's value of 0.81 is 92.9% above this industry median. Based on the distribution chart, Grey Wolf Health ranks #386 out of 562 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Grey Wolf Health has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Grey Wolf Health's Debt-to-Equity compare to ZTS?
According to the Healthcare Providers & Services industry distribution chart, Grey Wolf Health ranks #386 out of 562 companies for Debt-to-Equity. This places Grey Wolf Health in the lower half of its industry. The industry median Debt-to-Equity is 0.42. Grey Wolf Health's value of 0.81 is 92.9% above this benchmark. Historically, Grey Wolf Health's own Debt-to-Equity has ranged from 0.35 to 5.90 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.42, Grey Wolf Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grey Wolf Health's current Debt-to-Equity of 0.81 is 92.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Grey Wolf Health and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grey Wolf Health's current Debt-to-Equity is 0.81, which is 76% above median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grey Wolf Health stock overvalued right now?
Based on GuruFocus' analysis, Grey Wolf Health (TSXV:WOLF) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.09, compared to a current price of C$1.60 — trading 46.8% above its estimated fair value. The current Debt-to-Equity is 0.81, which is 76% above median its 10-year median of 0.46 and 92.9% above the Healthcare Providers & Services industry median of 0.42. Grey Wolf Health's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Grey Wolf Health (TSXV:WOLF), the current Debt-to-Equity is 0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grey Wolf Health (TSXV:WOLF) Overvalued in 2026?
Based on GuruFocus' analysis, Grey Wolf Health stock appears to be overvalued.
The current stock price of C$1.60 is trading 46.8% above its estimated GF Value™ of C$1.09.
GuruFocus considers Grey Wolf Health to be Significantly Overvalued.
Key valuation signals for TSXV:WOLF:
Debt-to-Equity: 0.81 (76% above median its 10-year median of 0.46)
GF Value™: C$1.09 vs. price of C$1.60 (46.8% above fair value)
Industry Position: 92.9% above the Healthcare Providers & Services median (#386 of 562)
No single metric tells the full story. See the TSXV:WOLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grey Wolf Animal Health Corp focuses on sourcing, in-licensing, acquiring, and compounding branded and generic products for sale in both animal and human health markets in Canada. The Company operates through two reportable segments: the Animal Health segment, which involves the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics across Canada; and the Pharmacy segment, which generates the majority of revenue and focuses on compounding pharmaceuticals for both human and animal health markets.
54GF Score
Get the complete analysis for TSXV:WOLF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WOLF has been successfully added to your 
